1-11 of 11
Lance K. Heilbrun
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer

Ulka N. Vaishampayan, Izabela Podgorski, Lance K. Heilbrun, Jawana M. Lawhorn-Crews, Kimberlee C. Dobson, Julie Boerner, Karri Stark, Daryn W. Smith, Elisabeth I. Heath, Joseph A. Fontana, Anthony F. Shields
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (2): 652–662.
https://doi.org/10.1158/1078-0432.CCR-18-1473
Published: 15 January 2019
View article titled, Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer
Open the PDF for Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients

Nader Sanai, Jing Li, Julie Boerner, Karri Stark, Jianmei Wu, Seongho Kim, Alanna Derogatis, Shwetal Mehta, Harshil D. Dhruv, Lance K. Heilbrun, Michael E. Berens, Patricia M. LoRusso
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (16): 3820–3828.
https://doi.org/10.1158/1078-0432.CCR-17-3348
Published: 14 August 2018
View article titled, Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients
Open the PDF for Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients in another window
Includes: Supplementary data
Journal Articles

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Patricia M. LoRusso, Jing Li, Angelika Burger, Lance K. Heilbrun, Edward A. Sausville, Scott A. Boerner, Daryn Smith, Mary Jo Pilat, Jie Zhang, Sara M. Tolaney, James M. Cleary, Alice P. Chen, Lawrence Rubinstein, Julie L. Boerner, Adam Bowditch, Dongpo Cai, Tracy Bell, Andrew Wolanski, Allison M. Marrero, Yiping Zhang, Jiuping Ji, Katherine Ferry-Galow, Robert J. Kinders, Ralph E. Parchment, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (13): 3227–3237.
https://doi.org/10.1158/1078-0432.CCR-15-0652
Published: 30 June 2016
View article titled, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
Open the PDF for Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer

Aung Naing, Razelle Kurzrock, Angelika Burger, Sachin Gupta, Xiudong Lei, Naifa Busaidy, David Hong, Helen X. Chen, Lawrence A. Doyle, Lance K. Heilbrun, Eric Rohren, Chaan Ng, Chandtip Chandhasin, Patricia LoRusso
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (18): 6052–6060.
https://doi.org/10.1158/1078-0432.CCR-10-2979
Published: 14 September 2011
View article titled, Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer
Open the PDF for Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer in another window
Journal Articles

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin

Ulka N. Vaishampayan, Angelika M. Burger, Edward A. Sausville, Lance K. Heilbrun, Jing Li, M. Naomi Horiba, Merrill J. Egorin, Percy Ivy, Simon Pacey, Patricia M. LoRusso
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14): 3795–3804.
https://doi.org/10.1158/1078-0432.CCR-10-0503
Published: 14 July 2010
View article titled, Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin
Open the PDF for Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin in another window
Journal Articles

Analysis and Reproducibility of 3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer

Anthony F. Shields, Jawana M. Lawhorn-Crews, David A. Briston, Sajad Zalzala, Shirish Gadgeel, Kirk A. Douglas, Thomas J. Mangner, Lance K. Heilbrun, Otto Muzik
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (14): 4463–4468.
https://doi.org/10.1158/1078-0432.CCR-07-5243
Published: 15 July 2008
View article titled, Analysis and Reproducibility of 3′-Deoxy-3′-[<sup>18</sup>F]Fluorothymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer
Open the PDF for Analysis and Reproducibility of 3′-Deoxy-3′-[<sup>18</sup>F]Fluorothymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer in another window
Journal Articles

Phase I Clinical Trial of BMS-247550, A Derivative of Epothilone B, Using Accelerated Titration 2B Design

Shirish M. Gadgeel, Antoinette Wozniak, Ramesh R. Boinpally, Richard Wiegand, Lance K. Heilbrun, Vikas Jain, Ralph Parchment, Dimitrios Colevas, Marvin B. Cohen, Patricia M. LoRusso
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (17): 6233–6239.
https://doi.org/10.1158/1078-0432.CCR-05-0127
Published: 06 September 2005
View article titled, Phase I Clinical Trial of BMS-247550, A Derivative of Epothilone B, Using Accelerated Titration 2B Design
Open the PDF for Phase I Clinical Trial of BMS-247550, A Derivative of Epothilone B, Using Accelerated Titration 2B Design in another window
Journal Articles

Cytochrome P450 and Glutathione Transferase Expression in Squamous Cell Cancer

Shadan Ali, Basil F. El-Rayes, Lance K. Heilbrun, Fazlul H. Sarkar, John F. Ensley, Omar Kucuk, Philip A. Philip
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (13): 4412–4416.
https://doi.org/10.1158/1078-0432.CCR-04-0145
Published: 06 July 2004
View article titled, Cytochrome P450 and Glutathione Transferase Expression in Squamous Cell Cancer
Open the PDF for Cytochrome P450 and Glutathione Transferase Expression in Squamous Cell Cancer in another window
Journal Articles

Cytochrome P450 and Glutathione Transferase Expression in Human Breast Cancer

Basil F. El-Rayes, Shadan Ali, Lance K. Heilbrun, Samir Lababidi, David Bouwman, David Visscher, Philip A. Philip
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (5): 1705–1709.
Published: 01 May 2003
View article titled, Cytochrome P450 and Glutathione Transferase Expression in Human Breast Cancer
Open the PDF for Cytochrome P450 and Glutathione Transferase Expression in Human Breast Cancer in another window
Journal Articles

A Phase II Trial of Bryostatin 1 in the Treatment of Metastatic Colorectal Cancer

Jeffrey A. Zonder, Anthony F. Shields, Mark Zalupski, Ruth Chaplen, Lance K. Heilbrun, Patricia Arlauskas, Philip A. Philip
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (1): 38–42.
Published: 01 January 2001
View article titled, A Phase II Trial of Bryostatin 1 in the Treatment of Metastatic Colorectal Cancer
Open the PDF for A Phase II Trial of Bryostatin 1 in the Treatment of Metastatic Colorectal Cancer in another window
Journal Articles

Phase I Pharmacokinetic Study of the Novel Antitumor Agent SR233377

Patricia M. LoRusso, Brenda J. Foster, Antoinette Wozniak, Lance K. Heilbrun, Julie I. McCormick, Paul E. Ruble, Martin A. Graham, Joseph Purvis, James Rake, Marion Drozd, Graham F. Lockwood, Thomas H. Corbett
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (8): 3088–3094.
Published: 01 August 2000
View article titled, Phase I Pharmacokinetic Study of the Novel Antitumor Agent SR233377
Open the PDF for Phase I Pharmacokinetic Study of the Novel Antitumor Agent SR233377 in another window